Last reviewed · How we verify
SH-1028
At a glance
| Generic name | SH-1028 |
|---|---|
| Sponsor | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations (PHASE3)
- The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers (PHASE1)
- The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 (PHASE1)
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions (PHASE1)
- A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC (PHASE2)
- Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer (PHASE1)
- Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SH-1028 CI brief — competitive landscape report
- SH-1028 updates RSS · CI watch RSS
- Nanjing Sanhome Pharmaceutical, Co., Ltd. portfolio CI